Top

Clinical Pharmacokinetics

Published in:

01-10-2018 | Original Research Article

Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

Authors: Ling Song, Yi Zhang, Ji Jiang, Shuang Ren, Li Chen, Dongyang Liu, Xijing Chen, Pei Hu

Published in: Clinical Pharmacokinetics | Issue 10/2018

Abstract

Aim

The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for sinogliatin (HMS-5552, dorzagliatin) by integrating allometric scaling (AS), in vitro to in vivo exploration (IVIVE), and steady-state concentration–mean residence time (C_ss-MRT) methods and to provide mechanistic insight into its pharmacokinetic properties in humans.

Methods

Human major pharmacokinetic parameters were analyzed using AS, IVIVE, and C_ss-MRT methods with available preclinical in vitro and in vivo data to understand sinogliatin drug metabolism and pharmacokinetic (DMPK) characteristics and underlying mechanisms. On this basis, an initial mechanistic PBPK model of sinogliatin was developed. The initial PBPK model was verified using observed data from a single ascending dose (SAD) study and further optimized with various strategies. The final model was validated by simulating sinogliatin pharmacokinetics under a fed condition. The validated model was applied to support a clinical drug–drug interaction (DDI) study design and to evaluate the effects of intrinsic (hepatic cirrhosis, genetic) factors on drug exposure.

Results

The two-species scaling method using rat and dog data (TS-_rat,dog) was the best AS method in predicting human systemic clearance in the central compartment (CL). The IVIVE method confirmed that sinogliatin was predominantly metabolized by cytochrome P450 (CYP) 3A4. The C_ss-MRT method suggested dog pharmacokinetic profiles were more similar to human pharmacokinetic profiles. The estimated CL using the AS and IVIVE approaches was within 1.5-fold of that observed. The C_ss-MRT method in dogs also provided acceptable prediction of human pharmacokinetic characteristics. For the PBPK approach, the 90% confidence intervals (CIs) of the simulated maximum concentration (C_max), CL, and area under the plasma concentration–time curve (AUC) of sinogliatin were within those observed and the 90% CI of simulated time to C_max (t_max) was closed to that observed for a dose range of 5–50 mg in the SAD study. The final PBPK model was validated by simulating sinogliatin pharmacokinetics with food. The 90% CIs of the simulated C_max, CL, and AUC values for sinogliatin were within those observed and the 90% CI of the simulated t_max was partially within that observed for the dose range of 25–200 mg in the multiple ascending dose (MAD) study. This PBPK model selected a final clinical DDI study design with itraconazole from four potential designs and also evaluated the effects of intrinsic (hepatic cirrhosis, genetic) factors on drug exposure.

Conclusions

Sinogliatin pharmacokinetic properties were mechanistically understood by integrating all four methods and a mechanistic PBPK model was successfully developed and validated using clinical data. This PBPK model was applied to support the development of sinogliatin.

Available only for authorised users

Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27(4):269–73. https://doi.org/10.5001/omj.2012.68.CrossRefPubMedPubMedCentral

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9. https://doi.org/10.2337/dc14-2441.CrossRefPubMed

Grewal AS, Sekhon BS, Lather V. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Mini Rev Med Chem. 2014;14(7):585–602.CrossRefPubMed

Filipski KJ, Pfefferkorn JA. A patent review of glucokinase activators and disruptors of the glucokinase–glucokinase regulatory protein interaction: 2011-2014. Expert Opin Ther Pat. 2014;24(8):875–91. https://doi.org/10.1517/13543776.2014.918957.CrossRefPubMed

Anderka O, Boyken J, Aschenbach U, Batzer A, Boscheinen O, Schmoll D. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem. 2008;283(46):31333–40. https://doi.org/10.1074/jbc.M805434200.CrossRefPubMed

Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301(5631):370–3. https://doi.org/10.1126/science.1084073.CrossRefPubMed

Xu H, Sheng L, Chen W, Yuan F, Yang M, Li H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. Drug Des Dev Ther. 2016;10:1619–26. https://doi.org/10.2147/dddt.s105021.CrossRef

Oie S, Tozer TN. Effect of altered plasma protein binding on apparent volume of distribution. J Pharm Sci. 1979;68(9):1203–5.CrossRefPubMed

Perrier D, Gibaldi M. Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther. 1974;191(1):17–24.PubMed

10.

Van den Bergh A, Sinha V, Gilissen R, Straetemans R, Wuyts K, Morrison D, et al. Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery. Clin Pharmacokinet. 2011;50(8):505–17. https://doi.org/10.2165/11587230-000000000-00000.CrossRefPubMed

11.

Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50–61. https://doi.org/10.1038/clpt.2012.65.CrossRefPubMed

12.

Xia B, Heimbach T, Lin TH, He H, Wang Y, Tan E. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions. Cancer Chemother Pharmacol. 2012;69(6):1567–82. https://doi.org/10.1007/s00280-012-1863-5.CrossRefPubMed

13.

Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918–33. https://doi.org/10.1007/s11095-006-9210-3.CrossRefPubMed

14.

Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. European Medicines Agency. CHMP458101.2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211315.pdf. Accessed 20 Mar 2018.

15.

Maekawa K, Harakawa N, Yoshimura T, Kim SR, Fujimura Y, Aohara F, et al. CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos. 2010;38(12):2100–4. https://doi.org/10.1124/dmd.110.034140.CrossRefPubMed

16.

Liu D, Song H, Song L, Liu Y, Cao Y, Jiang J, et al. A unified strategy in selection of the best allometric scaling methods to predict human clearance based on drug disposition pathway. Xenobiotica. 2016;46(12):1105–11. https://doi.org/10.1080/00498254.2016.1205761.CrossRefPubMed

17.

Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, et al. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharmacol Sin. 2015;36(12):1528–36. https://doi.org/10.1038/aps.2015.118.CrossRefPubMedPubMedCentral

18.

Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016;6(5):430–40. https://doi.org/10.1016/j.apsb.2016.04.004.CrossRefPubMedPubMedCentral

19.

Liu F, Zhuang X, Yang C, Li Z, Xiong S, Zhang Z, et al. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. Biopharm Drug Dispos. 2014;35(5):296–307. https://doi.org/10.1002/bdd.1897.CrossRefPubMed

20.

Fotaki N, Gray V, Krämer J, Diaz D, Flanagan T, Grove G. Dissolution highlights from the 2015 AAPS Annual Meeting in Orlando. Dissolut Technol. 2016;23(2):42–7. https://doi.org/10.14227/dt230216p42.CrossRef

21.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8(1):33–45.CrossRefPubMed

22.

Gabrielsson JL, Groth T. An extended physiological pharmacokinetic model of methadone disposition in the rat: validation and sensitivity analysis. J Pharmacokinet Biopharm. 1988;16(2):183–201.CrossRefPubMed

23.

Clinical drug interaction studies: study design, data analysis, and clinical implications guidance for industry. US Food and Drug Administration, CDER; 2017. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. Accessed 20 Mar 2018.

24.

Mano Y, Sugiyama Y, Ito K. Use of a physiologically based pharmacokinetic model for quantitative prediction of drug–drug interactions via CYP3A4 and estimation of the intestinal availability of CYP3A4 substrates. J Pharmaceut Sci. 2015;104(9):3183–93. https://doi.org/10.1002/jps.24495.CrossRef

25.

Vieira ML, Zhao P, Berglund EG, Reynolds KS, Zhang L, Lesko LJ, et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther. 2012;91(4):700–8. https://doi.org/10.1038/clpt.2011.305.CrossRefPubMed

26.

Pettit NN, Pisano J, Weber S, Ridgway J. Hepatic failure in a patient receiving itraconazole for pulmonary histoplasmosis—case report and literature review. Am J Ther. 2016;23(5):e1215–21. https://doi.org/10.1097/mjt.0000000000000313.CrossRefPubMed

27.

Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet. 2008;47(11):743–52. https://doi.org/10.2165/00003088-200847110-00005.CrossRefPubMed

28.

Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49(3):189–206. https://doi.org/10.2165/11318160-000000000-00000.CrossRefPubMed

29.

Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52(1 Suppl):91s–108s. https://doi.org/10.1177/0091270011415528.CrossRefPubMed

30.

Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat. 2004;23(1):100. https://doi.org/10.1002/humu.9210.CrossRefPubMed

31.

D’Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomed Simulations Resource; 2009. https://bmsr.usc.edu/software/adapt/citations/

32.

Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013;52(12):1085–100. https://doi.org/10.1007/s40262-013-0089-y.CrossRefPubMed

33.

Crewe HK, Barter ZE, Yeo KR, Rostami-Hodjegan A. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm Drug Dispos. 2011;32(6):303–18. https://doi.org/10.1002/bdd.760.CrossRefPubMed

34.

Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407–84. https://doi.org/10.1177/074823379701300401.CrossRefPubMed

35.

Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–5.CrossRefPubMed

Title: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics
Authors: Ling Song
Yi Zhang
Ji Jiang
Shuang Ren
Li Chen
Dongyang Liu
Xijing Chen
Pei Hu
Publication date: 01-10-2018
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 10/2018
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-018-0631-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

Abstract

Aim

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2018

Comment on van Rongen et al., “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”

Author’s Reply to Reith: “Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults”

Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis

Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study

Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives